HOOKIPA Pharma Inc. (HOOK): Price and Financial Metrics


HOOKIPA Pharma Inc. (HOOK)

Today's Latest Price: $11.07 USD

0.03 (-0.27%)

Updated Nov 27 1:00pm

Add HOOK to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

See all "A" rated Strong Buy stocks

HOOK Stock Price Chart Interactive Chart >

Price chart for HOOK

HOOK Price/Volume Stats

Current price $11.07 52-week high $14.37
Prev. close $11.10 52-week low $5.80
Day low $11.06 Volume 28,600
Day high $11.59 Avg. volume 67,670
50-day MA $10.17 Dividend yield N/A
200-day MA $10.00 Market Cap 241.89M

HOOKIPA Pharma Inc. (HOOK) Company Bio


HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.


HOOK Latest News Stream


Event/Time News Detail
Loading, please wait...

HOOK Latest Social Stream


Loading social stream, please wait...

View Full HOOK Social Stream

Latest HOOK News From Around the Web

Below are the latest news stories about HOOKIPA Pharma Inc that investors may wish to consider to help them evaluate HOOK as an investment opportunity.

HOOKIPA Pharma EPS beats by $0.19, beats on revenue

HOOKIPA Pharma (HOOK): Q2 GAAP EPS of -$0.28 beats by $0.19.Revenue of $6.69M (+65.2% Y/Y) beats by $3.2M.Press Release...

Seeking Alpha | August 13, 2020

HOOKIPA announces issuance of patents from US and EU

HOOKIPA Pharma (HOOK) announces that US and Europe have issued patents covering the company’s proprietary replicating arenavirus technology.The patents are granted to the University of Geneva as the company has exclusively licensed these patents from the University.The patent claims cover the company’s lead oncology product candidates HB-201 and HB-202."The newly issued...

Seeking Alpha | August 3, 2020

Read More 'HOOK' Stories Here

HOOK Price Returns

1-mo 11.71%
3-mo 20.07%
6-mo 2.50%
1-year 9.50%
3-year N/A
5-year N/A
YTD -9.48%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6738 seconds.